Caris Life Sciences, Inc. CAI
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 989.61M | 907.29M | 812.03M | 649.06M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 989.61M | 907.29M | 812.03M | 649.06M | -- |
| Cost of Revenue | 298.37M | 281.97M | 270.99M | 258.46M | -- |
| Gross Profit | 691.23M | 625.32M | 541.04M | 390.60M | -- |
| SG&A Expenses | 422.86M | 409.17M | 396.37M | 376.52M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 836.34M | 798.95M | 766.92M | 729.41M | -- |
| Operating Income | 153.26M | 108.35M | 45.11M | -80.34M | -- |
| Income Before Tax | 105.02M | 33.85M | -68.09M | -186.99M | -- |
| Income Tax Expenses | -111.00K | -134.00K | -- | -- | -- |
| Earnings from Continuing Operations | 105.14 | 33.98 | -68.09 | -186.99 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 105.14M | 33.98M | -68.09M | -186.99M | -- |
| EBIT | 153.26M | 108.35M | 45.11M | -80.34M | -- |
| EBITDA | 174.03M | 128.98M | 67.73M | -52.95M | -- |
| EPS Basic | 0.37 | -7.59 | -11.16 | -13.18 | -- |
| Normalized Basic EPS | 0.29 | -0.28 | -2.08 | -2.91 | -- |
| EPS Diluted | 0.35 | -7.61 | -11.17 | -13.19 | -- |
| Normalized Diluted EPS | 0.28 | -0.29 | -2.09 | -2.91 | -- |
| Average Basic Shares Outstanding | 1.13B | 911.80M | 664.86M | 418.30M | -- |
| Average Diluted Shares Outstanding | 1.16B | 940.78M | 693.84M | 433.41M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |